YU26202A - Derivati benzodiazepina - Google Patents

Derivati benzodiazepina

Info

Publication number
YU26202A
YU26202A YU26202A YUP26202A YU26202A YU 26202 A YU26202 A YU 26202A YU 26202 A YU26202 A YU 26202A YU P26202 A YUP26202 A YU P26202A YU 26202 A YU26202 A YU 26202A
Authority
YU
Yugoslavia
Prior art keywords
halo
lower alkyl
halogen
optionally substituted
lower alkoxy
Prior art date
Application number
YU26202A
Other languages
English (en)
Inventor
Adam Geo
Alexander Alanine
Erwin Goetschi
Vincent Mutel
Thomas Johannes Woltering
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of YU26202A publication Critical patent/YU26202A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja opšte formule (I) gde je X jednostruka veza ili etinedil grupa, gde je, u slučaju da je X jednostruka veza, R1 je halogen ili fenil koji je proizvoljno supstituisan sa halogenom, nižim alkilom, halogen-nižim alkilom, nižim alkoksi, halogen-nižim alkoksi, ili sa cijano; u slučaju da je X etinedil grupa, R1 je fenil, proizvoljno supstituisan sa halogenom, nižim alkilom, halogen-nižim alkilom, nižim cikloalkilom, nižim alkoksi ili halogen-nižim alkoksi; R3 je 5 ili 6 člani aril ili heteroaril aril ili heteroaril koji su proizvoljno supstituisani. Jedinjenja prema ovom pronalasku se mogu koristiti za tretiranje ili prevenciju akutnih i/ili hroničnih neuroloških poremećaja kao što su psihoza, šizofrenija, Alchajmerova bolest, spoznajni poremećaji i gubici pamćenja.[The present invention relates to compounds of general formula (I) wherein X is a single bond or an ethynediyl group, wherein, in case X is a single bond, R1 is halogen or phenyl which is optionally substituted with halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, or cyano; In case X is an ethynediyl group, R1 is phenyl, optionally substituted with halogen, lower alkyl, halo- lower alkyl, lower cycloalkyl, lower alkoxy or halo-lower alkoxy; R3 is a 5 or 6 membered aryl or heteroaryl which are optionally substituted. The compounds according to the present invention can be used for treating or preventing acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.
YU26202A 1999-10-15 2000-09-29 Derivati benzodiazepina YU26202A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120520 1999-10-15

Publications (1)

Publication Number Publication Date
YU26202A true YU26202A (sh) 2004-12-31

Family

ID=8239207

Family Applications (1)

Application Number Title Priority Date Filing Date
YU26202A YU26202A (sh) 1999-10-15 2000-09-29 Derivati benzodiazepina

Country Status (35)

Country Link
US (1) US6407094B1 (sh)
EP (1) EP1224174B1 (sh)
JP (1) JP3857138B2 (sh)
KR (1) KR100480320B1 (sh)
CN (1) CN1195522C (sh)
AR (1) AR026029A1 (sh)
AT (1) ATE250039T1 (sh)
AU (1) AU774451B2 (sh)
BR (1) BR0014859A (sh)
CA (1) CA2386974C (sh)
CO (1) CO5261604A1 (sh)
CZ (1) CZ20021653A3 (sh)
DE (1) DE60005386T2 (sh)
DK (1) DK1224174T3 (sh)
EG (1) EG24079A (sh)
ES (1) ES2204704T3 (sh)
GC (1) GC0000263A (sh)
HK (1) HK1051038A1 (sh)
HR (1) HRP20020259A2 (sh)
HU (1) HUP0203142A3 (sh)
IL (2) IL148816A0 (sh)
JO (1) JO2262B1 (sh)
MA (1) MA26831A1 (sh)
MY (1) MY125540A (sh)
NO (1) NO327817B1 (sh)
NZ (1) NZ517999A (sh)
PE (1) PE20010681A1 (sh)
PL (1) PL357418A1 (sh)
PT (1) PT1224174E (sh)
RU (1) RU2259360C2 (sh)
SI (1) SI1224174T1 (sh)
TR (1) TR200201023T2 (sh)
WO (1) WO2001029011A2 (sh)
YU (1) YU26202A (sh)
ZA (1) ZA200202544B (sh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201026T2 (tr) 1999-10-15 2002-08-21 F.Hoffmann-La Roche Ag Benzodiazepin türevleri
IL158021A0 (en) 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONIST I
NZ528315A (en) 2001-04-12 2005-04-29 F Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as MGLUR2 antagonists II
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
AU2003270166A1 (en) * 2002-09-10 2004-04-30 Novartis Ag Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
CA2532347C (en) * 2003-07-25 2012-03-27 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006048172A1 (en) 2004-11-05 2006-05-11 F. Hoffmann-La Roche Ag Process for preparation of isonicotinic acid derivatives
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2008128889A1 (en) * 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
BRPI0817269A2 (pt) * 2007-09-26 2014-10-07 Sinai School Medicine Análogos de azacitidina e usos dos mesmos
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
US8642626B2 (en) 2010-07-29 2014-02-04 Taisho Pharmaceutical Co., Ltd. Ethinyl-pyrazole derivative
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP2012153674A (ja) * 2011-01-28 2012-08-16 Astellas Pharma Inc ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体
WO2014064028A1 (en) 2012-10-23 2014-05-01 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of autistic disorders
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SI3096790T1 (sl) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
US9895324B2 (en) 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
CA2943877A1 (en) 2014-04-23 2015-10-29 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of intellectual disabilities
WO2015191630A1 (en) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法
CN109836356B (zh) * 2017-11-24 2022-03-08 沈阳化工研究院有限公司 一种芳甲醚衍生物及其应用
RU2702358C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов
CN114349779B (zh) * 2021-12-29 2023-09-26 智仑超纯环氧树脂(西安)有限公司 一种改性二氧化硅颗粒除氯剂及其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005109A1 (en) * 1995-07-31 1997-02-13 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂

Also Published As

Publication number Publication date
CN1195522C (zh) 2005-04-06
PE20010681A1 (es) 2001-06-28
PT1224174E (pt) 2004-01-30
KR20020038954A (ko) 2002-05-24
DE60005386T2 (de) 2004-06-24
JP3857138B2 (ja) 2006-12-13
MA26831A1 (fr) 2004-12-20
NZ517999A (en) 2004-07-30
ATE250039T1 (de) 2003-10-15
HRP20020259A2 (en) 2004-04-30
GC0000263A (en) 2006-11-01
HUP0203142A3 (en) 2003-03-28
CN1379765A (zh) 2002-11-13
WO2001029011A3 (en) 2001-11-08
ZA200202544B (en) 2003-09-23
NO20021690D0 (no) 2002-04-10
DE60005386D1 (de) 2003-10-23
US6407094B1 (en) 2002-06-18
JO2262B1 (en) 2004-10-07
NO20021690L (no) 2002-04-10
HUP0203142A2 (hu) 2003-02-28
EG24079A (en) 2008-05-11
EP1224174A2 (en) 2002-07-24
IL148816A (en) 2006-10-31
CO5261604A1 (es) 2003-03-31
JP2003512359A (ja) 2003-04-02
SI1224174T1 (en) 2003-12-31
AR026029A1 (es) 2002-12-26
IL148816A0 (en) 2002-09-12
RU2259360C2 (ru) 2005-08-27
BR0014859A (pt) 2002-07-16
CA2386974A1 (en) 2001-04-26
DK1224174T3 (da) 2004-01-26
AU774451B2 (en) 2004-06-24
KR100480320B1 (ko) 2005-04-07
HK1051038A1 (en) 2003-07-18
CZ20021653A3 (cs) 2002-08-14
PL357418A1 (en) 2004-07-26
WO2001029011A2 (en) 2001-04-26
AU7910200A (en) 2001-04-30
TR200201023T2 (tr) 2002-09-23
NO327817B1 (no) 2009-09-28
MY125540A (en) 2006-08-30
CA2386974C (en) 2009-10-13
EP1224174B1 (en) 2003-09-17
ES2204704T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
YU26202A (sh) Derivati benzodiazepina
YU27902A (sh) Derivati benzodiazepina
HUP0400851A2 (hu) Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 II antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NZ333706A (en) Benzenesulfone derivatives and medicaments
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
DE69328975D1 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
CA2252907A1 (en) Novel 2,3 disubstituted-4(3h)-quinazolinones
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
BR0209149A (pt) Ftalazinonas
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
NZ514037A (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders
MEP6708A (xx) Derivati n/tiayol/2/yl/benyamida
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
BG105710A (en) 5ht1 antagonists for antidepressant therapy
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
JO2307B1 (en) Papermidine derivatives
UA66888C2 (uk) 3-тетрагідропіридин-4-іл індоли, спосіб їх отримання та спосіб лікування психічних розладів
MXPA04005554A (es) Benzotiazoles.
DE60002292D1 (de) (3,4-dihydro-2h-benzo[1,4]oxazinyl-methyl)-3-(1h-indol-3-yl)-alkylamine
WO2000043375A3 (de) Substituierte arylheterocyclen
DE69916577D1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
AU3479299A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression